EPA,or bothlo the AREDS formulation did not further reduce risk

of progression to advancedAMD. Because ol the potential increased incidence of lung cancer with high doses of

3-carotene,Iutein<zeaxanthin could be an appropriate carotenoid substitute in the AREDSformulation.

Title:Ranibizumab and Bevacizumab for Neovascular Age Related Macular Degeneration

Purpose:loassess Ihc efficacy and safely of lanibizumab and bevacizumab and lo determine whether an as- needed

regimen wouldcompromise long-term VA,as compared with a monthly regimen

Methods:Patients with neovascular AMD where randomized to receive intravitreal injections of ranibizumab or

bevacizumab on either amonthly schedule or as needed withmonthly evaluation.The primary outcome was the

mean change in VA all year.

Results:Bevacizumab was equivalent loranibizumab whether it was administered monthly oi as needed.

Ranibizumab as needed was equivalent to monthly ranibizumab,but the comparison of bevacizumab as needed and

monthly was inconclusive.The mean decrease in centralretinal thickness was greater inthe ranibizumab-monthly

group than in the other groups. The rates of death,myocardial infarction,and stroke were not statistically different.

Conclusions:Bevacizumab and ranibizumab had equivalent effects on VA at1yr when administered according lo the

same schedule. There was no difference between ranibizumab given as needed and ranibizumab given monthly.

CAT! NEJM 2011:364(20):1897 908

GLAUCOMA

OHTS Arch Ophthalmol 2002:120(6|:701-13 Title:The Ocular Hypertension Treatment Study:a randomized trial determines lhal topicalocular hypotensive

medication delays or prevents the onset of primary open-angle glaucoma

Purpose: To determine the safety and efficacy ol topical ocular hypotensive medication indelaying or preventing Ihe

onsetolPOAG.

Methods:1636 patients with no evidence of glaucomatous damage and with I0P between 24-32 mmHg in one eye

and between 21-32 mmHg in the other eye were randomized lo observation or to treatment with commercially

available topical ocular hypotensive medication.Ihe primary outcome was developmental visual field abnormality

or optic disc deterioration attributed to POAG.

Results:Mean reduction inI0P in Ihe medication group was 22.5%t9.9% vs.4.0%i11.6% in the observation group.

At 5 years.Ihe probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group

(P- 0.0001).

Conclusions:Topical ocular hypotensivemedication was effective in delaying or preventing the onset of POAG in

individuals with elevated IOP.

Title:Latanoprost for open-angle glaucoma (UKGTS):a randomised,multicentre,placebo-controlled trial

Purpose: To assess vision preservation in patients given latanoprost compared with those given placebo.

Methods:Patients with newly diagnosed POAG were randomized lo receive cither latanoprost 0.005% or placebo

eye drops.The primary outcome was time to visual field deteriorationwithin 24 months.